Lifespan
46
3
4
27
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
15.2%
7 terminated/withdrawn out of 46 trials
79.4%
-7.1% vs industry average
15%
7 trials in Phase 3/4
48%
13 of 27 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (46)
Online Tai Chi Plus Fitbit After ACS
Role: collaborator
Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sex Trafficking
Role: lead
TMS for PTSD and Blood Pressure
Role: lead
Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders
Role: collaborator
Injectable Buprenorphine in Prison: A Preference Trial
Role: lead
Reducing Alcohol Use and Sexual Dysfunction in Survivors of Sexual Trauma
Role: lead
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Role: collaborator
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Role: collaborator
Stress Reactivity and Mother-Infant Cardiovascular Disease Risk
Role: lead
Implementing Low-Barrier HCV Treatment in a Jail Setting
Role: lead
Mindfulness & Mechanisms Study
Role: lead
Symptom Management Implementation of Patient Reported Outcomes in Oncology
Role: collaborator
Rhode Island Diastolic Dysfunction - Heart Failure
Role: collaborator
Hydroxyurea Optimization Through Precision Study
Role: lead
Integrated Alcohol and Sexual Assault Prevention for Bisexual Women
Role: lead
Effects of Tildrakizumab on Epigenetic Age
Role: collaborator
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
Role: lead
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Role: collaborator
Prenatal Mindfulness & Hypertension Study
Role: lead
Integrated Alcohol and Sexual Assault Intervention for College Men
Role: lead